SAREPTA THERAPEUTICS, INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
SAREPTA THERAPEUTICS, INC. (SRPT) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-08-05
- SAREPTA THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-06-30 was $0.00.
- SAREPTA THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $5.23M, a 85.20% decline from fiscal 2024.
- SAREPTA THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $35.36M, a 55.91% decline from fiscal 2023.
- SAREPTA THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $80.20M, a 100.48% increase from fiscal 2022.
- SAREPTA THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $40.01M, a 202.50% increase from fiscal 2021.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $0.00 10-Q · filed 2026-08-05 | $0.00 derived: sum of 3 quarters · filed 2026-08-05 | $0.00 derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-06 | $0.00 derived: sum of 2 quarters · filed 2026-05-06 | $0.00 derived: sum of 3 quarters · filed 2026-05-06 | $0.00 derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $0.00 derived: sum of 2 quarters · filed 2026-03-02 | $0.00 derived: sum of 3 quarters · filed 2026-08-05 | $5.23M 10-K · filed 2026-03-02 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2026-08-05 | $5.23M 10-Q · filed 2025-11-06 | $20.23M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $5.23M 10-Q · filed 2026-08-05 | $20.23M derived: sum of 3 quarters · filed 2026-08-05 | $38.58M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $5.23M 10-Q · filed 2026-05-06 | $20.23M derived: sum of 2 quarters · filed 2026-05-06 | $38.58M derived: sum of 3 quarters · filed 2026-05-06 | $40.32M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $14.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $33.34M derived: sum of 2 quarters · filed 2026-03-02 | $35.09M derived: sum of 3 quarters · filed 2026-03-02 | $35.36M 10-K · filed 2026-03-02 |
| 2024-09-30 | $18.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $20.09M derived: sum of 2 quarters · filed 2025-11-06 | $20.37M 10-Q · filed 2025-11-06 | $20.72M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $1.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $2.02M 10-Q · filed 2025-08-06 | $2.38M derived: sum of 3 quarters · filed 2026-03-02 | $6.35M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $275.00K 10-Q · filed 2025-05-06 | $632.00K derived: sum of 2 quarters · filed 2026-03-02 | $4.60M derived: sum of 3 quarters · filed 2026-03-02 | $80.20M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $357.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $4.33M derived: sum of 2 quarters · filed 2026-03-02 | $79.92M derived: sum of 3 quarters · filed 2026-03-02 | $80.20M 10-K · filed 2026-03-02 |
| 2023-09-30 | $3.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $79.57M derived: sum of 2 quarters · filed 2024-11-06 | $79.85M 10-Q · filed 2024-11-06 | $107.57M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $75.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $75.88M 10-Q · filed 2024-08-07 | $103.60M derived: sum of 3 quarters · filed 2025-02-28 | $104.47M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $280.00K 10-Q · filed 2024-05-01 | $28.00M derived: sum of 2 quarters · filed 2025-02-28 | $28.88M derived: sum of 3 quarters · filed 2025-02-28 | $36.18M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $27.73M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $28.60M derived: sum of 2 quarters · filed 2025-02-28 | $35.90M derived: sum of 3 quarters · filed 2025-02-28 | $40.01M 10-K · filed 2025-02-28 |
| 2022-09-30 | $874.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $8.18M derived: sum of 2 quarters · filed 2023-11-01 | $12.28M 10-Q · filed 2023-11-01 | $12.36M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $7.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $11.41M 10-Q · filed 2023-08-02 | $11.48M derived: sum of 3 quarters · filed 2024-02-28 | $14.05M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $4.11M 10-Q · filed 2023-05-02 | $4.18M derived: sum of 2 quarters · filed 2024-02-28 | $6.75M derived: sum of 3 quarters · filed 2024-02-28 | $16.43M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $77.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $2.64M derived: sum of 2 quarters · filed 2024-02-28 | $12.32M derived: sum of 3 quarters · filed 2024-02-28 | $13.22M 10-K · filed 2024-02-28 |
| 2021-09-30 | $2.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $12.25M derived: sum of 2 quarters · filed 2022-11-02 | $13.15M 10-Q · filed 2022-11-02 | $34.83M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $9.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02 | $10.58M 10-Q · filed 2022-08-02 | $32.26M derived: sum of 3 quarters · filed 2023-02-28 | $32.32M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $901.00K 10-Q · filed 2022-05-04 | $22.58M derived: sum of 2 quarters · filed 2023-02-28 | $22.64M derived: sum of 3 quarters · filed 2023-02-28 | $35.45M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $21.68M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $21.74M derived: sum of 2 quarters · filed 2023-02-28 | $34.54M derived: sum of 3 quarters · filed 2023-02-28 | $59.33M 10-K · filed 2023-02-28 |
| 2020-09-30 | $61.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $12.86M derived: sum of 2 quarters · filed 2021-11-03 | $37.65M 10-Q · filed 2021-11-03 | |
| 2020-06-30 | $12.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $37.59M 10-Q · filed 2021-08-04 | ||
| 2020-03-31 | $24.78M 10-Q · filed 2021-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |